1801 — Innovent Biologics Cashflow Statement
0.000.00%
Last trade - 00:00- HK$89.33bn
- HK$83.95bn
- CNY9.42bn
Annual cashflow statement for Innovent Biologics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | — |
| Source: | ARS | ARS | ARS | ARS | |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | fx Preliminary |
| Net Income/Starting Line | -859 | -3,051 | -2,170 | -1,144 | — |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 939 | 938 | -312 | 389 | — |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -474 | -117 | 244 | 518 | — |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -308 | -2,025 | -1,919 | 148 | — |
| Capital Expenditures | -522 | -1,848 | -1,366 | -1,382 | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -4,663 | -851 | -69.7 | 383 | — |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -5,185 | -2,698 | -1,435 | -999 | — |
| Financing Cash Flow Items | -88.6 | -132 | 73.6 | -54.6 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 4,912 | 5,003 | 2,892 | 2,587 | — |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -1,150 | 83.2 | -343 | 1,730 | — |